Breaking News, Financial News

Financial Report: Alkermes

Key commercial products up 22% in the quarter

Alkermes
 
2Q Revenues: $138.6 million (-9%)
 
2Q Earnings: $7.3 million (earnings were $22.4 million 2Q12)
 
Comments: Revenues from the company’s five key commercial products for the quarter grew 22% to $98.9 million. Manufacturing and royalty revenues from Risperdal Consta and Invega Sustenna/Xeplion were $56.2 million, up 16%. Manufacturing and royalty revenues from Ampyra/Fampyra were $19.9 million, up 16%. Net sales of Vivitrol were $17.4 million, up 40%. Royalty revenue from Bydureon was $5.4 million, up 80%. 2Q12 results included $20.0 million of intellectual property license revenue.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters